Medindia

X

Signalife Announces Webcast

Tuesday, April 8, 2008 General News J E 4
Advertisement
GREENVILLE, S.C., April 7, 2008 Signalife, Inc.(AMEX: SGN) has confirmed that it has filed its form 10-KSB, and the company'sChairman and Chief Executive Officer, Dr. Lowell T. Harmison, has scheduled awebcast on April 14, 2008, at 10:00 a.m. EST.

Dr. Harmison stated: "Now that Signalife has closed filing the company'sform 10-KSB and the Company is manufacturing and shipping product, I ampleased to provide direction on new contracts, pending orders and production,various product initiatives (from the Fidelity 100 to the prospectiveindustry-wide application of the Fidelity 1000 module), and the Athletes ForLife partnership, as well as such issues as the Company's immediate, positivefinancial prospects as well as several other initiatives that have now beencompleted. The webcast will be broadcast from a studio and will be attended byrepresentatives of Athletes for Life Foundation and selected invited membersof the business press. To the extent time permits, I will answer questionsfollowing my presentation. I urge all persons following the company to viewthe webcast."

You may access the webcast athttp://www.videonewswire.com/event.asp?id=47313 and will have the opportunityto submit written questions over the internet. You may also view or review thewebcast for a 12-month period at the same website address (please allowseveral hours for Signalife to effectuate this archival link). All individualsviewing the original webcast or any replay are reminded that the webcast iscopyrighted by the company and cannot be recorded or rebroadcast without thecompany's express written consent.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring,detection and prevention of disease through continuous biomedical signalmonitoring. Signalife uses its patented signal technology to design anddevelop medical devices, therapies and/or technologies that simplify andreduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbolSGN. More information is located at www.signalife.com. Clear Data. TrustedResults.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as"forward- looking statements", which are intended to convey our expectationsor predictions regarding the occurrence of possible future events or theexistence of trends and factors that may impact our future plans and operatingresults. Any statements in this news release that are not statements ofhistorical fact maybe considered to be forward-looking statements. Theseforward-looking statements are derived, in part, from various assumptions andanalyses we have made in the context of our current business plan andinformation currently available to us and in light of our experience andperceptions of historical trends, current conditions and expected futuredevelopments and other factors we believe to be appropriate in thecircumstances. You can generally identify forward-looking statements throughwords and phrases such as "seek", "anticipate", "believe", "estimate","expect", "intend", "plan", "budget", "project", "may be", "may continue","may likely result", and similar expressions. Each forward-looking statementshould be read in context with, and with an understanding of, the variousother disclosures concerning our company and our business made in this newsrelease as well as other public reports we file with the SEC, as they may beamended. You should not place undue reliance on any forward-looking statementas a prediction of actual results or developments. We are not obligated toupdate or revise any forward-looking statement contained in this news releaseto reflect new events or circumstances unless and to the extent required byapplicable law.SOURCE Signalife, Inc.-0- 04/07/2008

/CONTACT: Dr. Lowell T. Ha
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Keryx Biopharmaceuticals Announces Implementation ...
S
Quark Pharmaceuticals, Inc. Closes $27 Million Fin...